Search research articles
Contact Us
Filters
Showing results (41-50 of 48) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 48 results.
Cancer Research Communications
|
June 5, 2026
p97 Inhibition Synergistically Enhances Hypomethylating Therapy Through Targeting of PLK1 in Acute Myeloid Leukemia
Steffan T Nawrocki, Ning Wang, Claudia M Espitia, et al.
Leukemia Research
|
December 10, 2020
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆
Karen Yee, Cristina Papayannidis, Norbert Vey, et al.
The Lancet. Haematology
|
September 16, 2021
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study
Kevin R Kelly, Sikander Ailawadhi, David S Siegel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2018
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma
Kevin R Kelly, Jonathan W Friedberg, Steven I Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2015
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Michael Andreeff, Kevin R Kelly, Karen Yee, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
January 17, 2025
Exploring treatment-driven subclonal evolution of prognostic triple biomarkers: Dual gene fusions and chimeric RNA variants in novel subtypes of acute myeloid leukemia patients with KMT2A rearrangement
Yi Xu, Shengwen Calvin Li, Jeffrey Xiao, et al.
Blood
|
October 20, 2022
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
Naval G Daver, Monique Dail, Jacqueline S Garcia, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 20, 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
Marina Y Konopleva, Monique Dail, Naval G Daver, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 48) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 48 results.
Cancer Research Communications
|
June 5, 2026
p97 Inhibition Synergistically Enhances Hypomethylating Therapy Through Targeting of PLK1 in Acute Myeloid Leukemia
Steffan T Nawrocki, Ning Wang, Claudia M Espitia, et al.
Leukemia Research
|
December 10, 2020
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆
Karen Yee, Cristina Papayannidis, Norbert Vey, et al.
The Lancet. Haematology
|
September 16, 2021
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study
Kevin R Kelly, Sikander Ailawadhi, David S Siegel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2018
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma
Kevin R Kelly, Jonathan W Friedberg, Steven I Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2015
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Michael Andreeff, Kevin R Kelly, Karen Yee, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
January 17, 2025
Exploring treatment-driven subclonal evolution of prognostic triple biomarkers: Dual gene fusions and chimeric RNA variants in novel subtypes of acute myeloid leukemia patients with KMT2A rearrangement
Yi Xu, Shengwen Calvin Li, Jeffrey Xiao, et al.
Blood
|
October 20, 2022
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
Naval G Daver, Monique Dail, Jacqueline S Garcia, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 20, 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial
Marina Y Konopleva, Monique Dail, Naval G Daver, et al.
Page
of 5